OR WAIT 15 SECS
Scientific advancement and innovation shared the spotlight at the 4th Annual Glaucoma 360 meeting, presented by the Glaucoma Research Foundation (GRF). The meeting brought together leaders in research, industry, ophthalmology, and philanthropy with one goal–to find a cure for glaucoma.
The three-day event, co-chaired by Andrew Iwach, MD, and Adrienne Graves, PhD, centered around the Glaucoma 360 Annual Gala, the New Horizons Forum, and the CME Symposium. Glaucoma 360 was held Feb. 5-7, in San Francisco.
Andrew Iwach, MD, welcomes readers to Ophthalmology Times' coverage of the 2015 Glaucoma 360 meeting.
The Glaucoma 360 Annual Gala featured the presentation of The 2015 Catalyst Award and Visionary Award.
The Catalyst Award was presented to Adrienne Graves, PhD, a global ophthalmic leader who has dedicated her career to advancing innovative concepts so patients could preserve their vision. Dr. Graves has been involved with GRF for many years, serving as a board member and co-developer of Glaucoma 360.
The Visionary Award was shared by Nobel Laureate Shinya Yamanaka, MD, PhD, and Masayo Takahaski, MD, PhD, who was 2014 Stem Cell Person of the Year. Both researchers were honored for their pioneer work to improve global healthcare and treating blinding eye disease.
Paul P. Lee, MD, kicked off the New Horizons Forum by delivering the Drs. Henry and Frederick Sutro Memorial Lecture. Dr. Lee addressed the future challenges facing ophthalmologists as well as the opportunities that those challenges will present.
The nucleus of the New Horizons Forum followed with a range of talks on innovation, drugs, devices, and drug delivery. The day-long program also looked at the future of glaucoma research and presented FDA’s new guidance to development.
Dr. Lee returned to the podium to deliver the Shaffer-Hetherington-Hoskins Lecture during the CME Symposium. Dr. Lee’s presentation looked at how science and art combine to improve patient outcomes.
The CME Symposium also featured discussions on the latest clinical advances to treating patients with glaucoma. This special report from Ophthalmology Times, “the official partner and media sponsor” for Glaucoma 360, highlights some of the presentations from the meeting. To experience the meeting to its fullest, readers are encouraged to download the Ophthalmology Times app and interact with the presentations through on-line exclusives, videos, and podcasts.